Skip to Main Content

Updated with stock prices.

It’s Monday, which means Wall Street is having a say about the results from a long-anticipated clinical trial of the cholesterol-lowering drug Praluent that were presented Saturday by Regeneron Pharmaceuticals and Sanofi.


Praluent, given by injection, reduced the risk of death for patients with high cholesterol — a landmark finding in the field of cardiology, doctors said, marking the first time since the statin era that a cholesterol-lowering drug has demonstrated a significant effect on whether patients live or die.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.